Antidiabetic Effect of Beta vulgaris Mixture: Regulation of Glycolytic Enzymes and Pancreatic Beta Cells

Dae Sik Haam¹, Dong-Yeop Shin², Hak Yong Lee², Young Mi Park², Byeong-Soo Kim³, Myung-Sunny Kim⁴, Hye Jeong Yang^4, and Na-Rae Shin^4,

¹Baeryeo Innovation, 217, Jungang-ro, Jeju-si, Jeju, Republic of Korea

²INVIVO Co. Ltd,. 121, Daehak-ro, Nonsan 32992, Republic of Korea

³Department of Integrated Life Science and Tecnology, Kongju National University, 54, Daehak-ro, Yesan-eup, Yesan-gun, Chungcheongnam-do, Republic of Korea

⁴Korea Food Research Institute, 245, Nongsaengmyeong-ro, Iseo-myeon, Wanju-gun, Jeollabuk-do 55365, Republic of Korea

Cite this paper:
Dae Sik Haam, Dong-Yeop Shin, Hak Yong Lee, Young Mi Park, Byeong-Soo Kim, Myung-Sunny Kim, Hye Jeong Yang and Na-Rae Shin. Antidiabetic Effect of Beta vulgaris Mixture: Regulation of Glycolytic Enzymes and Pancreatic Beta Cells. Journal of Food and Nutrition Research. 2022; 10(1):32-40. doi: 10.12691/jfnr-10-1-5

Abstract

Diabetes is a chronic metabolic disease with a high prevalence worldwide. Beet (Beta vulgaris) is a plant that is widely used in many countries and has various biological activities. In this study, we aimed to evaluate the antidiabetic effect of a B. vulgaris mixture (BM). In the in vitro evaluation, we measured the inhibitory activities of α-amylase and α-glucosidase, performed the oral starch tolerance test (OATT) and oral sucrose tolerance test (OSTT) in Sprague Dawley (SD) rats, and evaluated the clinical symptoms, oral glucose tolerance test (OGTT), number of blood cells, and insulin resistance in db/db mice. BM showed an inhibitory effect against α-amylase and α-glucosidase activity and decreased the blood glucose increased in the OATT and OSTT. In the diabetes mouse model, BM alleviated the general symptoms of diabetes and OGTT results showed a decrease in the increased blood sugar level. Regarding diabetes-related tissue weight, BM decreased the reduced pancreatic weight and showed an effect on diabetes-related factors of blood. Histological analysis indicated that BM decreased insulin concentration, insulin resistance, and insulin secretion ability in serum, and increased insulin concentration in the islets of Langerhans. These results demonstrate that BM has an antidiabetic effect through the regulation of glycolytic enzymes and β cell activity in the pancreas.

Keywords:
beta vulgaris diabetes glycolytic enzymes pancreas β cell

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Wilcox, G., “Insulin and Insulin Resistance” Clinical Biochemist Reviews 26(2). 19-39. May. 2005.
[2]	Paschou, S.A., Papadopoulou-Marketou, N., Chrousos, G.P., Kanaka-Gantenbein, C., “On type 1 diabetes mellitus pathogenesis” Endocrine Connections 7(1). R38-R46. Jan. 2018.
[3]	Sena, C.M., Bento, C.F., Pereira, P., Seica, R., “Diabetes mellitus: new challenges and innovative therapies” EPMA Journal 1(1). 138-163. Mar. 2010.
[4]	Petersen, M.C., Vatner, D.F., Shulman, G.I., “Regulation of hepatic glucose metabolism in health and disease” Nature Reviews Endocrinology 13(10). 572-587. Oct. 2017.
[5]	Chen, Y., Zhao, X., Wu, H., “Metabolic Stress and Cardiovascular Disease in Diabetes Mellitus: The Role of Protein O-GlcNAc Modification” Arteriosclerosis, Thrombosis, and Vascular Biology 39(10). 1911-1924. Oct. 2019.
[6]	Szunerits, S., Melinte, S., Barras, A., Pagneux, Q., Voronova, A., Abderrahmani, A., et al., “The impact of chemical engineering and technological advances on managing diabetes: present and future concepts” Chemical Society Reviews 50(3). 2102-2146. Feb. 2021.
[7]	Gui, Q.F., Xu, Z.R., Xu, K.Y., Yang, Y.M., “The Efficacy of Ginseng-Related Therapies in Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-analysis” Medicine (Baltimore). 95(6). e2584. Feb. 2016.
[8]	Pivari, F., Mingione, A., Brasacchio, C., Soldati, L., “Curcumin and Type 2 Diabetes Mellitus: Prevention and Treatment” Nutrients. 11(8). 1837. Aug. 2019.
[9]	Gheith, I., El-Mahmoudy, A., “Laboratory evidence for the hematopoietic potential of Beta vulgaris leaf and stalk extract in a phenylhydrazine model of anemia” Brazilian Journal of Medical and Biological Research 51(11). e7722. Oct. 2018.
[10]	Albasher, G., Almeer, R., Alarifi, S., Alkhtani, S., Farhood, M., Al-Otibi, F.O., et al., “Nephroprotective Role of Beta vulgaris L. Root Extract against Chlorpyrifos-Induced Renal Injury in Rats” Evidence-Based Complementary and Alternative Medicine 2019. 3595761. Nov. 2019.
[11]	Sulakhiya, K., Patel, V.K., Saxena, R., Dashore, J., Srivastava, A.K., Rathore, M., “Effect of Beta vulgaris Linn. Leaves Extract on Anxiety- and Depressive-like Behavior and Oxidative Stress in Mice after Acute Restraint Stress” Pharmacognosy Research 8(1). 1-7. Jan-Mar. 2016.
[12]	Hajihosseini, S., Setorki, M., Hooshmandi, Z., “The antioxidant activity of Beta vulgaris leaf extract in improving scopolamine-induced spatial memory disorders in rats” Avicenna Journal of Phytomedicine 7(5). 417-425. Sep-Oct. 2017.
[13]	Chentli, F., Azzoug, S., Mahgoun, S., “Diabetes mellitus in elderly” Indian Journal of Endocrinology and Metabolism 19(6). 744-752. Nov-Dec. 2015.
[14]	Fu, Z., Gilbert, E.R., Liu, D., “Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes” Current Diabetes Reviews 9(1). 25-53. Jan. 2013.
[15]	van de Laar, F.A., “Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes” Vascular Health and Risk Management 4(6) 1189-1195. 2008.
[16]	Verma, J., Awasthi, C., Jamal, Q.M., Siddiqui, M.H., Wadhwa, G., Kesari, K.K., “α-Amylase Inhibitor’s Performance in the Control of Diabetes Mellitus: An Application of Computational Biology” Current trends in Bioinformatics 307-332. Jul. 2018.
[17]	de Souza, P.M., de Oliveira Magalhaes, P., “Application of microbial α-amylase in industry - A review” Brazilian Journal of Microbiology 41(4) 850-861. Oct. 2010.
[18]	Peyrot des Gachons, C., Breslin, P.A., “Salivary Amylase: Digestion and Metabolic Syndrome” Current Diabetes Reports 16(10) 102. Oct. 2016.
[19]	Proenca, C., Freitas, M., Ribeiro, D., Oliverira, E.F.T., Sousa, J.L.C., et al., “α-Glucosidase inhibition by flavonoids: an in vitro and in silico structure–activity relationship study” Journal of Enzyme Inhibition and Medicinal Chemisty 32(1) 1216-1228. Dec. 2017.
[20]	Cnop, M., Welsh, N., Jonas, J.C., Jorns, A., Lenzen, S., Eizirik, D.L., “Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities” Diabetes 54(Suppl). S97-107. Dec. 2005.
[21]	Wang, B., Chandrasekera, P.C., Pippin, J.J., “Leptin- and leptin receptor-deficient rodent models: relevance for human type 2 diabetes” Current Diabetes Reviews 10(2) 131-145. Mar. 2014.
[22]	Deshpande, A.D., Harris-Hayes, M., Schootman, M., “Epidemiology of diabetes and diabetes-related complications” Physical Therapy 88(11) 1254-1264. Nov. 2008.
[23]	Lee, J.E., “Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol” Annals of Pediatric Endocrinology and Metabolism 20(2). 74-78. Jun. 2015.
[24]	Leon, B.M., Maddox, T.M., “Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research” World Journal of Diabetes 6(13). 1246-1258. Oct. 2015.
[25]	Schofield, J.D., Liu, Y., Rao-Balakrishna, P., Malik, R.A., Soran, H., “Diabetes Dyslipidemia” Diabetes Therapy 7(2) 203-219. Jun. 2016.
[26]	Chen, C., Cohrs, C.M., Stertmann, J., Bozsak, R, Speier, S., “Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis” Molecular Metabolism 6(9). 943-957. Jul. 2017.
[27]	Ormazabal, V., Nair, S., Elfeky, O., Aguayo, C., Salomon, C., Zuniga, F.A., “Association between insulin resistance and the development of cardiovascular disease” Cardiovascular Diabetology 17(1) 112. Aug. 2018.
[28]	Remedi, M.S., Emfinger, C., “Pancreatic β-cell identity in diabetes” Diabetes Obesity and Metabolism 18 Suppl 1(Suppl 1). 110-116. Sep. 2016.
[29]	Cerf, M.E., “Beta Cell Dysfunction and Insulin Resistance” Front Endocrinol (Lausanne) 4. 37. Mar. 2013.